Switch to Colistin Monotherapy - Not Recommended
In a patient with amikacin-susceptible Acinetobacter baumannii urinary tract infection who is failing therapy with new fever, you should ADD colistin to amikacin rather than switching to colistin monotherapy. The organism remains susceptible to amikacin, and combination therapy offers superior microbiological eradication while preventing resistance emergence.
Rationale for Combination Therapy
Amikacin Remains Appropriate for UTI
The FDA label explicitly states that amikacin is indicated for infections caused by susceptible Acinetobacter species, and "a dose of 250 mg twice daily may be used" specifically for uncomplicated urinary tract infections 1. Since your isolate is amikacin-susceptible, there is no microbiological justification to discontinue it.
Colistin Combination Superior to Monotherapy
While recent high-quality RCTs show no mortality benefit for colistin-carbapenem combinations in severe CRAB infections 2, the evidence specifically demonstrates:
- Microbiological eradication is significantly superior with combination therapy (OR: 1.88,95% CI = 1.13-3.12, p = 0.01) compared to colistin monotherapy 3
- No difference in mortality or nephrotoxicity between monotherapy and combination approaches 3
- The colistin-amikacin combination is particularly effective at eradicating persister cells, especially when colistin is given first followed by amikacin 4
Prevention of Resistance Development
Critical evidence shows that:
- Colistin monotherapy at high concentrations fails to prevent colistin dependence in A. baumannii 5
- Combinations of colistin with amikacin at subinhibitory concentrations successfully eradicate strains by inhibiting colistin dependence development 5
- Sequential exposure (colistin then amikacin) completely eliminated persister cells within 6 hours, while reverse order left 0.016% persisters remaining 4
Clinical Algorithm
Step 1: Verify Susceptibility
- Confirm amikacin susceptibility remains valid
- Check colistin MIC if available (target ≤2 mg/L)
- Rule out heteroresistance if clinical suspicion exists 6
Step 2: Add Colistin to Existing Amikacin
Colistin dosing for UTI:
- Loading dose: 5 mg CBA/kg IV 7
- Maintenance: 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h 7
- Monitor renal function closely given nephrotoxicity risk 7
Continue amikacin:
Step 3: Reassess at 48-72 Hours
- Clinical response (fever resolution, symptom improvement)
- Repeat urine culture to document microbiological clearance
- If no response by 3-5 days, consider source control issues or alternative resistance mechanisms 1
Important Caveats
Nephrotoxicity Risk
Both agents carry nephrotoxicity risk. The combination does not increase nephrotoxicity compared to colistin alone 3, but requires:
Colistin Limitations in Urine
Colistin achieves variable urinary concentrations. However, for systemic manifestations (fever, potential bacteremia from UTI source), systemic colistin levels are relevant. The combination approach addresses both urinary and potential systemic infection.
Duration of Therapy
- 5-7 days for complicated UTI 7
- Extend to 10-14 days only if bacteremia documented 7
- Reassess need for continued therapy beyond 10 days with repeat cultures and clinical assessment 1
Why Not Switch to Colistin Alone?
Switching to colistin monotherapy would:
- Abandon an agent to which the organism is susceptible
- Reduce microbiological eradication rates 3
- Increase risk of colistin resistance emergence 5
- Provide no mortality or clinical cure advantage over combination 3, 8
The 2022 ESCMID guidelines acknowledge that while colistin-carbapenem combinations show no benefit for severe CRAB infections 2, this applies to carbapenem-resistant isolates. Your scenario involves an amikacin-susceptible organism where maintaining susceptible agent coverage is standard antimicrobial stewardship practice.